Resistance to anaplastic lymphoma kinase inhibitors: knowing the enemy is half the battle won

The bedrock of resistance to TKI is that, after the diagnosis, we face with a different disease that needs to be re-characterized through tissue or/and liquid biopsies. Understanding molecular pathways driving the resistant phenotype will give us the chance to know what we are dealing with and, rather than choose an empirical approach, will help us to properly define the best targeted treatment for these patients. READ ARTICLE

Translational Lung Cancer Research DOI: 10.21037/tlcr-20-372

Authors: Tabbò F, Reale ML, Bironzo P, Scagliotti GV.

Real-World OutcomesKirk SmithDecember 9, 2020ALK, acquired mutations, ALK inhibitor, clonal evolution, resistance